CARISMA Therapeutics (FRA:W2J) Other Stockholders Equity: €0.00 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CARISMA Therapeutics Other Stockholders Equity?

CARISMA Therapeutics FRA:W2J Other Stockholders Equity is €0.00 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

CARISMA Therapeutics's Other Stockholders Equity for the quarter that ended in Sep. 2025 was €0.00 Mil.

CARISMA Therapeutics's quarterly Other Stockholders Equity declined from Mar. 2025 (€0.00 Mil) to Jun. 2025 (€-0.00 Mil) but then increased from Jun. 2025 (€-0.00 Mil) to Sep. 2025 (€0.00 Mil).

CARISMA Therapeutics's annual Other Stockholders Equity declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€-0.00 Mil) and declined from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€-0.00 Mil).

CARISMA Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Other Stockholders Equity Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity
-0.00 -0.00 0.00 -0.00 -0.00

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 -0.00 0.00

CARISMA Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
CARISMA Therapeutics (FRA:W2J) has a Other Stockholders Equity of €0.00 Mil as of Sep. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Other Stockholders Equity too high?
CARISMA Therapeutics' current Other Stockholders Equity is €0.00 Mil.
How does CARISMA Therapeutics' Other Stockholders Equity compare to SCPX and CYTOF?
CARISMA Therapeutics' Other Stockholders Equity of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
CARISMA Therapeutics (FRA:W2J) has a current Other Stockholders Equity of €0.00 Mil. The stock's GF Value™ is €18.82, compared to a current price of €0.03 — trading 99.9% below its estimated fair value. The current Other Stockholders Equity is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For CARISMA Therapeutics (FRA:W2J), the current Other Stockholders Equity is €0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Other Exchanges CARM:USA
Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.